Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer

Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD-1) antibody, programmed cell death ligand 1 (PD-L1) antibody, and cytotoxic T lymphocyte associated protein 4 (CTLA-4) antibody...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy, Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer
Formato:	article
Lenguaje:	ZH
Publicado:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2021
Materias:	lung neoplasms immunotherapy immune checkpoint inhibitors tumor mutational burden expert consensus Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/73efbbca7aad481c9495e49e699bda8c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:73efbbca7aad481c9495e49e699bda8c
record_format	dspace
spelling	oai:doaj.org-article:73efbbca7aad481c9495e49e699bda8c2021-11-19T06:49:15ZExpert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer1009-34191999-618710.3779/j.issn.1009-3419.2021.101.40https://doaj.org/article/73efbbca7aad481c9495e49e699bda8c2021-11-01T00:00:00Zhttp://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.40https://doaj.org/toc/1009-3419https://doaj.org/toc/1999-6187Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD-1) antibody, programmed cell death ligand 1 (PD-L1) antibody, and cytotoxic T lymphocyte associated protein 4 (CTLA-4) antibody. It has brought significant survival benefits to some patients with advanced lung cancer and changed the treatment pattern of advanced lung cancer. Previous studies have shown that the objective response rate of PD-1/PD-L1 antibody in advanced non-small cell lung cancer (NSCLC) is only about 20%. So reliable biomarkers are urgently needed to screen out the potential benefit population of ICIs and improve the clinical response rate. Tumor mutational burden (TMB) is an emerging biomarker of immunotherapy in addition to PD-L1 expression. There is little correlation between PD-L1 expression and TMB in lung cancer. It is estimated that TMB can expand the benefit population of immunotherapy. However, in clinical practice, the detection of TMB, the determination of cut-off value and the clinical guidance strategy are still not standardized. This consensus will give guiding suggestions on the detection and application scenarios of TMB, so as to promote the standardization of TMB application for immunotherapy in lung cancer.Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted TherapyChinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung CancerChinese Anti-Cancer Association; Chinese Antituberculosis Associationarticlelung neoplasmsimmunotherapyimmune checkpoint inhibitorstumor mutational burdenexpert consensusNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ZHChinese Journal of Lung Cancer, Vol 24, Iss 11, Pp 743-752 (2021)
institution	DOAJ
collection	DOAJ
language	ZH
topic	lung neoplasms immunotherapy immune checkpoint inhibitors tumor mutational burden expert consensus Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	lung neoplasms immunotherapy immune checkpoint inhibitors tumor mutational burden expert consensus Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
description	Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD-1) antibody, programmed cell death ligand 1 (PD-L1) antibody, and cytotoxic T lymphocyte associated protein 4 (CTLA-4) antibody. It has brought significant survival benefits to some patients with advanced lung cancer and changed the treatment pattern of advanced lung cancer. Previous studies have shown that the objective response rate of PD-1/PD-L1 antibody in advanced non-small cell lung cancer (NSCLC) is only about 20%. So reliable biomarkers are urgently needed to screen out the potential benefit population of ICIs and improve the clinical response rate. Tumor mutational burden (TMB) is an emerging biomarker of immunotherapy in addition to PD-L1 expression. There is little correlation between PD-L1 expression and TMB in lung cancer. It is estimated that TMB can expand the benefit population of immunotherapy. However, in clinical practice, the detection of TMB, the determination of cut-off value and the clinical guidance strategy are still not standardized. This consensus will give guiding suggestions on the detection and application scenarios of TMB, so as to promote the standardization of TMB application for immunotherapy in lung cancer.
format	article
author	Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer
author_facet	Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer
author_sort	Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy
title	Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
title_short	Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
title_full	Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
title_fullStr	Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
title_full_unstemmed	Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
title_sort	expert consensus on tumor mutational burden for immunotherapy in lung cancer
publisher	Chinese Anti-Cancer Association; Chinese Antituberculosis Association
publishDate	2021
url	https://doaj.org/article/73efbbca7aad481c9495e49e699bda8c
work_keys_str_mv	AT chinesesocietyofclinicaloncologyexpertcommitteeontumorvasculartargetedtherapy expertconsensusontumormutationalburdenforimmunotherapyinlungcancer AT chinesesocietyofclinicaloncologyexpertcommitteeonnonsmallcelllungcancer expertconsensusontumormutationalburdenforimmunotherapyinlungcancer
_version_	1718420320041304064

Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer

Ejemplares similares